A detailed history of Bessemer Group Inc transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Bessemer Group Inc holds 5,215 shares of BMRN stock, worth $368,074. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,215
Previous 5,215 -0.0%
Holding current value
$368,074
Previous $455,000 5.71%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

SELL
$76.22 - $98.51 $8,155 - $10,540
-107 Reduced 2.01%
5,215 $503,000
Q3 2023

Nov 13, 2023

BUY
$85.07 - $94.48 $9,102 - $10,109
107 Added 2.05%
5,322 $471,000
Q4 2022

Feb 13, 2023

SELL
$80.93 - $108.63 $31,967 - $42,908
-395 Reduced 7.04%
5,215 $540,000
Q3 2022

Nov 09, 2022

BUY
$82.16 - $96.94 $460,917 - $543,833
5,610 New
5,610 $476,000
Q2 2022

Aug 10, 2022

SELL
$71.48 - $86.85 $28,091 - $34,132
-393 Closed
0 $0
Q4 2021

Jan 27, 2022

SELL
$71.72 - $91.47 $12,048 - $15,366
-168 Reduced 29.95%
393 $35,000
Q3 2021

Nov 12, 2021

SELL
$74.77 - $85.47 $5,682 - $6,495
-76 Reduced 11.93%
561 $43,000
Q1 2021

May 13, 2021

BUY
$74.73 - $90.69 $44,838 - $54,414
600 Added 1621.62%
637 $48,000
Q2 2020

Aug 05, 2020

BUY
$79.55 - $124.22 $2,943 - $4,596
37 New
37 $5,000
Q4 2019

Feb 04, 2020

SELL
$64.27 - $86.37 $20.2 Million - $27.1 Million
-314,132 Closed
0 $0
Q3 2019

Nov 07, 2019

SELL
$67.4 - $85.11 $1.47 Million - $1.86 Million
-21,868 Reduced 6.51%
314,132 $21.2 Million
Q2 2019

Jul 19, 2019

BUY
$80.35 - $93.9 $27 Million - $31.5 Million
335,874 Added 266566.66%
336,000 $28.8 Million
Q1 2019

May 13, 2019

BUY
$84.2 - $98.62 $6,567 - $7,692
78 Added 162.5%
126 $11,000
Q4 2018

Feb 12, 2019

BUY
$80.14 - $106.07 $3,846 - $5,091
48 New
48 $4,000
Q1 2018

May 10, 2018

SELL
$77.67 - $92.63 $27,184 - $32,420
-350 Closed
0 $0
Q3 2017

Nov 03, 2017

BUY
$80.6 - $94.95 $28,209 - $33,232
350
350 $33,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $13.1B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Bessemer Group Inc Portfolio

Follow Bessemer Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bessemer Group Inc with notifications on news.